Protective Effects of Topiroxostat on an Ischemia-Reperfusion Model of Rat Hearts

Area of Science:

• Cardiovascular Research
• Oxidative Stress Biology
• Pharmacology

Background:

• Ischemia/reperfusion (I/R) injury causes cardiac dysfunction through reactive oxygen species (ROS) generation.
• Xanthine oxidase (XO) is a primary source of ROS, making its inhibition a potential strategy for cardioprotection.
• The efficacy of XO inhibitors like topiroxostat and allopurinol in mitigating I/R injury remains to be fully elucidated.

Purpose of the Study:

• To evaluate the cardioprotective effects of topiroxostat and allopurinol against cardiac I/R injury.
• To compare the potency of topiroxostat, allopurinol, and N-acetylcysteine (NAC) in mitigating I/R-induced damage.

Main Methods:

• Isolated rat hearts were subjected to I/R, with assessments of ventricular function, arrhythmias, XO activity, thiobarbituric acid reactive substances (TBARS), adenine nucleotides, and cardiomyocyte death markers.
• Measurements included creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) release during reperfusion.

Main Results:

• Topiroxostat significantly improved ventricular function and reduced arrhythmias during I/R, while inhibiting myocardial XO activity and TBARS production.
• Allopurinol and NAC showed similar protective effects but required higher concentrations.
• All tested agents reduced xanthine levels and the release of CPK and LDH, indicating reduced myocardial damage.

Conclusions:

• Topiroxostat demonstrates potent cardioprotective effects against I/R injury, superior to allopurinol and NAC.
• The mechanism involves significant inhibition of XO activity and subsequent suppression of ROS generation, as evidenced by reduced TBARS production.